Recursion Pharmaceuticals, Inc. - Class A (RXRX)
RXRX moved a median of -0.14% 30 minutes after news, and -0.54% by the close. How RXRX actually reacts to news — the realized, point-in-time move the market made, measured across 683 labeled events over the last three years with zero look-ahead.
RXRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.16% | 43% | 681 |
| 30-min | -0.14% | 47% | 681 |
| 60-min | -0.34% | 42% | 681 |
| to close | -0.54% | 42% | 682 |
| Middle 50% of RXRX reactions | -1.56% to +1.36% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 683 |
Half of all Recursion Pharmaceuticals, Inc. - Class A news events land between -1.56% and +1.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RXRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 47 | -0.36% | 43% | -1.14% |
| Price-target cuts | 13 | -0.54% | 46% | -1.06% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how RXRX ranks against every other measured name →
That’s how RXRX usually reacts — get an email when it moves on news →Email me when RXRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RXRX's baseline. Nothing else.
Recent RXRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K RECURSION PHARMACEUTICAL For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +3.42% | +13.97% | |
| Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone | Press release | GlobeNewswire | +3.42% | +13.97% | |
| Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock | Press release | GlobeNewswire | +3.42% | +13.97% | |
| Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration | Press release | GlobeNewswire | +3.42% | +13.97% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -1.15% | +1.28% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.16% | +2.92% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +2.92% | |
| Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Press release | GlobeNewswire | +0.16% | +2.92% | |
| Recursion to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.01% | +1.85% | |
| Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Press release | GlobeNewswire | +0.00% | +4.95% | |
| Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th | Press release | GlobeNewswire | +0.49% | -1.98% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.41% | -0.31% | |
| Recursion to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.05% | -1.90% | |
| Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Press release | GlobeNewswire | -1.56% | +7.37% | |
| Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City | Press release | GlobeNewswire | -0.18% | +2.52% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.16% | +7.52% | |
| Form 8-K RECURSION PHARMACEUTICAL For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.16% | +7.52% | |
| Recursion Reports First Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.16% | +7.52% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | -2.02% | |
| Form ARS RECURSION PHARMACEUTICAL For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.91% | -2.02% | |
| Form DEF 14A RECURSION PHARMACEUTICAL For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | -0.91% | -2.02% | |
| Form DEFA14A RECURSION PHARMACEUTICAL | SEC filing · Form DEFA14A | SEC EDGAR | -0.91% | -2.02% | |
| Recursion Announces Board Transition | Press release | GlobeNewswire | -0.91% | -2.02% | |
| Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 | Press release | GlobeNewswire | -1.63% | -2.08% | |
| Recursion to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.32% | +2.08% | |
| Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | Press release | GlobeNewswire | +1.90% | +5.86% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | +1.29% | |
| Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer | Press release | GlobeNewswire | +1.71% | -1.25% | |
| Form 10-K RECURSION PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.53% | -3.83% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -1.53% | -3.83% | |
| Form S-8 RECURSION PHARMACEUTICAL | SEC filing · Form S-8 | SEC EDGAR | -1.53% | -3.83% | |
| Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.53% | -3.83% | |
| Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC | Press release | GlobeNewswire | +0.73% | +0.29% | |
| Recursion to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.73% | +0.29% | |
| Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 | Press release | GlobeNewswire | +0.33% | +14.61% | |
| Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Press release | GlobeNewswire | -1.48% | -4.02% | |
| AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift | Press release | PR Newswire | -0.34% | -2.70% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.05% | |
| Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +3.10% | +4.36% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -3.21% | |
| Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 | Press release | GlobeNewswire | +1.57% | -2.24% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +1.15% | |
| Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 | Press release | GlobeNewswire | +1.87% | +3.48% | |
| Form 10-Q RECURSION PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.20% | -1.98% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -1.98% | |
| Recursion Announces CEO Transition Plan to Drive Next Phase of Growth | Press release | GlobeNewswire | -0.20% | -1.98% | |
| Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.20% | -1.98% | |
| Recursion to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.53% | -4.03% | |
| Form 8-K RECURSION PHARMACEUTICAL For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -1.84% | |
| Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th | Press release | GlobeNewswire | -0.75% | -4.68% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RXRX section they belong to.
Where else RXRX is measured.
RXRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Recursion Pharmaceuticals, Inc. - Class A's median reaction calculated?
Every labeled RXRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 683 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of RXRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RXRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.